Mr Boucher is a senior executive at the multi-national animal health company Zoetis. Prior to Zoetis, he successfully executed a range of strategic transactions at Board level in the pharmaceutical and diagnostics industries and played a key role as Chief Business Officer at Vivacta in the $90m sale of the diagnostic start-up to Novartis in 2012. Prior to that, Mr. Boucher held senior commercial and business roles in a succession of biotech companies after having gained executive level experience for seven years as a director of business development at GSK. Before joining industry, Mr. Boucher was a patent attorney in London, Montreal and Paris. Mr. Boucher has a broad network within the global life sciences sector in particular in drug development and finance where his connections will provide access to the range of skill sets relevant to Vasgen’s future success. Mr Boucher was a partner of the USA-based Technology Commercialisation Group (TCG) which provides transaction execution capability and interim management services for medical life science companies on both sides of the Atlantic. He was interim Executive Director and member of the Board at Bioxodes S.A. and is a Fellow of the Royal Society of Medicine. Mr. Boucher was educated in genetics and molecular biology at University of Cambridge, UK, and earned an MBA from INSEAD Business School.
Innovative ocular and cancer therapeutics